 |
PDBsum entry 1bqi
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Use of papain as a model for the structure-Based design of cathepsin k inhibitors: crystal structures of two papain-Inhibitor complexes demonstrate binding to s'-Subsites.
|
 |
|
Authors
|
 |
J.M.Lalonde,
B.Zhao,
W.W.Smith,
C.A.Janson,
R.L.Desjarlais,
T.A.Tomaszek,
T.J.Carr,
S.K.Thompson,
H.J.Oh,
D.S.Yamashita,
D.F.Veber,
S.S.Abdel-Meguid.
|
 |
|
Ref.
|
 |
J Med Chem, 1998,
41,
4567-4576.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Papain has been used as a surrogate enzyme in a drug design effort to obtain
potent and selective inhibitors of cathepsin K, a new member of the papain
superfamily of cysteine proteases that is selectively and highly expressed in
osteoclasts and is implicated in bone resorption. Here we report the crystal
structures of two papain-inhibitor complexes and the rational design of novel
cathepsin K inhibitors. Unlike previously known crystal structures of
papain-inhibitor complexes, our papain structures show ligand binding extending
deep within the S'-subsites. The two inhibitor complexes,
carbobenzyloxyleucinyl-leucinyl-leucinal and
carbobenzyloxy-L-leucinyl-L-leucinyl methoxymethyl ketone, were refined to 2.2-
and 2.5-A resolution with R-factors of 0.190 and 0. 217, respectively. The
S'-subsite interactions with the inhibitors are dominated by an
aromatic-aromatic stacking and an oxygen-aromatic ring edge interaction. The
knowledge of S'-subsite interactions led to a design strategy for an inhibitor
spanning both subsites and yielded a novel, symmetric inhibitor selective for
cathepsin K. Simultaneous exploitation of both S- and S'-sites provides a
general strategy for the design of cysteine protease inhibitors having high
specificity to their target enzymes.
|
 |
|
|
|
|
 |